MX2019008126A - Formulaciones de toxina botulinica libres de albumina. - Google Patents
Formulaciones de toxina botulinica libres de albumina.Info
- Publication number
- MX2019008126A MX2019008126A MX2019008126A MX2019008126A MX2019008126A MX 2019008126 A MX2019008126 A MX 2019008126A MX 2019008126 A MX2019008126 A MX 2019008126A MX 2019008126 A MX2019008126 A MX 2019008126A MX 2019008126 A MX2019008126 A MX 2019008126A
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- albumin
- toxin formulations
- free botulinum
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Esta invención se relaciona con las formulaciones de toxina botulínica que se estabilizan sin el uso de algún excipiente proteico. La invención también se relaciona con los métodos para preparar y usar tales formulaciones de toxina botulínica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22043309P | 2009-06-25 | 2009-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008126A true MX2019008126A (es) | 2019-09-09 |
Family
ID=43381023
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000174A MX344583B (es) | 2009-06-25 | 2010-06-25 | Formulaciones de toxina botulinica libres de albumina. |
MX2016002034A MX366344B (es) | 2009-06-25 | 2010-06-25 | Formulaciones de toxina botulinica libres de albumina. |
MX2019008126A MX2019008126A (es) | 2009-06-25 | 2012-01-02 | Formulaciones de toxina botulinica libres de albumina. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000174A MX344583B (es) | 2009-06-25 | 2010-06-25 | Formulaciones de toxina botulinica libres de albumina. |
MX2016002034A MX366344B (es) | 2009-06-25 | 2010-06-25 | Formulaciones de toxina botulinica libres de albumina. |
Country Status (13)
Country | Link |
---|---|
US (5) | US9340587B2 (es) |
EP (1) | EP2445521A4 (es) |
JP (1) | JP6043627B2 (es) |
KR (5) | KR102192618B1 (es) |
CN (1) | CN102869373B (es) |
AU (1) | AU2010265888A1 (es) |
BR (1) | BRPI1015938A2 (es) |
CA (1) | CA2766521C (es) |
CO (1) | CO6491076A2 (es) |
IL (2) | IL268980B (es) |
MX (3) | MX344583B (es) |
SG (1) | SG177357A1 (es) |
WO (1) | WO2010151840A2 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
KR100852824B1 (ko) * | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
CN102499981B (zh) * | 2005-03-03 | 2016-08-03 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
HUE037595T2 (hu) | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
MX344583B (es) | 2009-06-25 | 2016-12-20 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
CN102666396B (zh) * | 2009-10-21 | 2015-05-13 | 雷文斯治疗公司 | 用于纯化非复合的肉毒杆菌神经毒素的方法和系统 |
NO2661276T3 (es) * | 2011-01-07 | 2017-12-30 | ||
JP2015514074A (ja) * | 2012-03-22 | 2015-05-18 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 局所化学的神経麻痺薬を使用して皺を処置する方法 |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
KR20180099912A (ko) * | 2013-09-08 | 2018-09-05 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
EP3760186A1 (en) * | 2014-04-30 | 2021-01-06 | Allergan, Inc. | Formulations of biologics for intravesical instillation |
TWI669129B (zh) * | 2014-12-23 | 2019-08-21 | 德商梅茲製藥有限兩合公司 | 預填充式玻璃容器及其套組與使用 |
SG11201706247VA (en) | 2015-02-03 | 2017-08-30 | Merz Pharma Gmbh & Co Kgaa | Botulinum toxin prefilled container |
KR20180077202A (ko) * | 2015-10-29 | 2018-07-06 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법 |
WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
WO2018038585A1 (ko) * | 2016-08-26 | 2018-03-01 | 주식회사 에이비바이오 | 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법 |
US10369190B2 (en) * | 2016-09-13 | 2019-08-06 | Allergan, Inc. | Non-protein clostridial toxin compositions |
BR112019010131A2 (pt) * | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
KR101744900B1 (ko) * | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
EP3624819A4 (en) * | 2017-05-18 | 2021-03-24 | Revance Therapeutics, Inc. | METHOD OF TREATMENT OF CERVICAL DYSTONIA |
AU2018290765A1 (en) * | 2017-06-26 | 2020-01-23 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
KR102063475B1 (ko) * | 2018-02-22 | 2020-01-09 | 주식회사 에이비바이오 | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 |
KR102324855B1 (ko) * | 2020-05-20 | 2021-11-11 | 오스템임플란트 주식회사 | 보툴리눔 독소를 포함하는 약제학적 액상 조성물 |
KR102414997B1 (ko) * | 2020-09-29 | 2022-06-29 | 주식회사 엘지생활건강 | 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물 |
US20230365957A1 (en) * | 2020-10-07 | 2023-11-16 | Pro-Tox Inc. | Vacuum drying method for botulinum toxin |
US20240050538A1 (en) * | 2020-12-18 | 2024-02-15 | Atgc Co., Ltd. | Pharmaceutical composition for long-term storage of liquid formulation of botulinum toxin |
KR102427362B1 (ko) * | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
WO1994007510A1 (en) | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
EP2027872B1 (en) | 1993-12-28 | 2010-07-14 | Allergan, Inc. | Neurotoxic component of a botulinum toxin for treating tardive dyskinesia |
US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US20030095927A1 (en) | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
EP1053014A4 (en) | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
IL149778A0 (en) | 1999-11-22 | 2002-11-10 | Universal Preservation Technologies Inc | Preservation of sensitive biological material |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
BR0108173A (pt) | 2000-02-08 | 2003-01-21 | Allergan Inc | Composições farmacêuticas de toxina de botulina |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US6670322B2 (en) | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US7807780B2 (en) * | 2000-07-21 | 2010-10-05 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
WO2003000193A2 (en) | 2001-06-21 | 2003-01-03 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
ES2536709T3 (es) | 2002-02-14 | 2015-05-27 | Chugai Seiyaku Kabushiki Kaisha | Utilización de ácido acético para eliminar los problemas inducidos por el ión Fe en las formulaciones de anticuerpos anti-HM1.24 o anti-IL6R |
WO2003101483A1 (en) | 2002-05-31 | 2003-12-11 | Solux Corporation | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US9265725B2 (en) * | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) * | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
RU2206337C1 (ru) | 2002-10-29 | 2003-06-20 | Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" | Лекарственный препарат для лечения мышечных дистоний и способ его получения |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
MXPA06009898A (es) * | 2004-03-03 | 2008-02-07 | Revance Therapeutics Inc | Composiciones y metodos para la aplicacion topica y suministro transdermico de toxinas botulinicas. |
AU2005251676B2 (en) * | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
KR100852824B1 (ko) * | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
US20070196364A1 (en) * | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
PT2813239T (pt) * | 2004-08-04 | 2017-06-09 | Ipsen Biopharm Ltd | Composição farmacêutica contendo a neurotoxina botulínica a2 |
GB2419526A (en) * | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
EP1778279B1 (en) | 2004-08-04 | 2014-12-03 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
US7727537B2 (en) * | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
US7838011B2 (en) * | 2005-02-14 | 2010-11-23 | Pankaj Modi | Stabilized protein compositions for topical administration and methods of making same |
US9314431B2 (en) * | 2005-02-14 | 2016-04-19 | Transdermal Corp | Solubilized benzoyl small molecule |
CN102499981B (zh) * | 2005-03-03 | 2016-08-03 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8568740B2 (en) * | 2005-11-17 | 2013-10-29 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US7899450B2 (en) * | 2006-03-01 | 2011-03-01 | Telecommunication Systems, Inc. | Cellular augmented radar/laser detection using local mobile network within cellular network |
US20090123527A1 (en) * | 2006-07-24 | 2009-05-14 | Akorn, Inc. | Method of inducing topical anesthesia and transdermal patch |
WO2008079464A2 (en) * | 2006-09-08 | 2008-07-03 | Becton, Dickinson And Company | Stable powder formulations of alum-adsorbed vaccines |
US20100150994A1 (en) * | 2006-12-01 | 2010-06-17 | Anterios, Inc. | Amphiphilic entity nanoparticles |
AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
FR2910327B1 (fr) * | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
NZ598039A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
WO2008145359A1 (en) | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
KR101087017B1 (ko) * | 2007-07-10 | 2011-12-09 | (주)메디톡스 | 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물 |
CN102872447B (zh) * | 2007-07-26 | 2015-09-30 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
WO2009056651A1 (en) * | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
KR20110106346A (ko) | 2008-12-10 | 2011-09-28 | 알러간, 인코포레이티드 | 클로스트리디움 독소 약제학적 조성물 |
HUE037595T2 (hu) * | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
MX344583B (es) * | 2009-06-25 | 2016-12-20 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
MX2012000372A (es) * | 2009-07-06 | 2012-02-28 | Variation Biotechnologies Inc | Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas. |
US20110059079A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody Coformulations |
CN102666396B (zh) * | 2009-10-21 | 2015-05-13 | 雷文斯治疗公司 | 用于纯化非复合的肉毒杆菌神经毒素的方法和系统 |
CN102639183B (zh) * | 2009-10-30 | 2016-05-04 | 雷文斯治疗公司 | 用于局部施用治疗或美容组合物的装置和方法 |
CN102596145B (zh) * | 2009-10-30 | 2016-08-24 | 杜杰克特医疗系统有限公司 | 瓶间转移系统 |
EP2627318B1 (en) * | 2010-10-12 | 2017-08-16 | Merz Pharma GmbH & Co. KGaA | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
NO2661276T3 (es) * | 2011-01-07 | 2017-12-30 | ||
RU2640922C1 (ru) * | 2011-03-31 | 2018-01-12 | Меди-Токс Инк. | Лиофилизированный препарат ботулотоксина |
WO2013130535A1 (en) * | 2012-02-27 | 2013-09-06 | Newgen Biopharma Corporation | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
WO2014066916A2 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
TWI669129B (zh) | 2014-12-23 | 2019-08-21 | 德商梅茲製藥有限兩合公司 | 預填充式玻璃容器及其套組與使用 |
KR20180077202A (ko) * | 2015-10-29 | 2018-07-06 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법 |
FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and use thereof |
AU2017250267A1 (en) * | 2016-04-12 | 2018-11-08 | Illustris Pharmaceuticals, Inc. | Compositions for topical application of compounds |
HUE052023T2 (hu) | 2016-05-27 | 2021-04-28 | Ipsen Biopharm Ltd | Triptofánnal vagy tirozinnal stabilizált folyékony neurotoxin készítmény |
WO2019046311A1 (en) * | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
US20200390871A1 (en) * | 2017-11-03 | 2020-12-17 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect |
US20200384090A1 (en) * | 2017-12-04 | 2020-12-10 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
-
2010
- 2010-06-25 MX MX2012000174A patent/MX344583B/es active IP Right Grant
- 2010-06-25 CN CN201080035225.0A patent/CN102869373B/zh active Active
- 2010-06-25 KR KR1020197012292A patent/KR102192618B1/ko active IP Right Grant
- 2010-06-25 SG SG2011096153A patent/SG177357A1/en unknown
- 2010-06-25 MX MX2016002034A patent/MX366344B/es unknown
- 2010-06-25 KR KR1020127001439A patent/KR101804279B1/ko active IP Right Grant
- 2010-06-25 KR KR1020217037163A patent/KR20210141783A/ko active Application Filing
- 2010-06-25 KR KR1020207035805A patent/KR102328155B1/ko active IP Right Grant
- 2010-06-25 WO PCT/US2010/040104 patent/WO2010151840A2/en active Application Filing
- 2010-06-25 US US12/824,118 patent/US9340587B2/en active Active
- 2010-06-25 IL IL268980A patent/IL268980B/en unknown
- 2010-06-25 AU AU2010265888A patent/AU2010265888A1/en not_active Abandoned
- 2010-06-25 EP EP10792770.9A patent/EP2445521A4/en active Pending
- 2010-06-25 JP JP2012517802A patent/JP6043627B2/ja not_active Expired - Fee Related
- 2010-06-25 BR BRPI1015938A patent/BRPI1015938A2/pt not_active IP Right Cessation
- 2010-06-25 KR KR1020177034374A patent/KR101975051B1/ko active IP Right Grant
- 2010-06-25 CA CA2766521A patent/CA2766521C/en active Active
- 2010-06-25 US US13/380,131 patent/US20120107361A1/en not_active Abandoned
-
2011
- 2011-12-22 IL IL217156A patent/IL217156A0/en unknown
-
2012
- 2012-01-02 MX MX2019008126A patent/MX2019008126A/es unknown
- 2012-01-25 CO CO12010852A patent/CO6491076A2/es not_active Application Discontinuation
-
2016
- 2016-05-16 US US15/155,341 patent/US10111939B2/en active Active
-
2018
- 2018-10-30 US US16/175,434 patent/US11351232B2/en active Active
-
2021
- 2021-05-18 US US17/322,901 patent/US11911449B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008126A (es) | Formulaciones de toxina botulinica libres de albumina. | |
PH12019500627A1 (en) | Affinity-oligonucleotide conjugates and uses thereof | |
MX2022012374A (es) | Composiciones multi-suplementos. | |
PH12018500950A1 (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
MX2012006549A (es) | Composiciones y metodos que comprenden variantes de proteasa. | |
GB0917002D0 (en) | Improved shigella blebs | |
MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
MX2020005446A (es) | Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento. | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
MX2009004862A (es) | Estabilizacion de vacunas por liofilizacion. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
JO3755B1 (ar) | تركيبات تستوستيرون | |
MX349948B (es) | Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae. | |
EP2557919A4 (en) | STABILIZED FORMULATIONS OF STATIN | |
HK1133642A1 (en) | Azaadamantane ester and carbamate derivatives and methods of use thereof | |
MA32321B1 (fr) | Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers | |
MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
MX2015012905A (es) | Formulaciones de factor viii recombinantes. | |
MX2023003000A (es) | Formulaciones de liberacion modificada de viloxacina. | |
MX2017003165A (es) | Jabones antimicrobianos que contienen carvacrol y metodos de uso de los mismos. | |
GB2509470A (en) | Pharmaceutical compositions of antihypertensives | |
TN2010000463A1 (en) | Compositions and methods for preparing and using same | |
EP2575766A4 (en) | NEW PHARMACEUTICAL COMPOUNDS |